Why the study?
Identifying patients with HCM most likely to benefit from prophylactic ICDs remains challenging, with low positive predictive value for appropriate discharges and substantial complication rates.
Current risk stratification for sudden cardiac death in hypertrophic cardiomyopathy has significant gaps, leading to low predictive value for appropriate ICD therapies and exposing patients to substantial device-related complications.
Current risk stratification may expose HCM patients to unnecessary ICDs; leaves open the need for better predictors before wider adoption.
Sudden cardiac death (SCD) is the most dramatic and catastrophic complication of hypertrophic cardiomyopathy (HCM),1 with an annual rate of >1%.1 The identification of those patients most likely to benefit from prophylacticimplantable cardioverter defibrillators remains challenging in children and adults. The positive predictive value for appropriate discharges is low (≈20%), and the complication rates in this younger, active population is substantial, including lead problems, infections, inappropriate discharges, and psychological issues
No takes yet. Share an insight, caveat, or question.
Pelliccia et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: